Insider Buying: DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Buys $1,234,453.50 in Stock

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) major shareholder Jan Stahlberg bought 182,882 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were bought at an average cost of $6.75 per share, for a total transaction of $1,234,453.50. Following the completion of the purchase, the insider owned 8,134,740 shares of the company’s stock, valued at $54,909,495. This represents a 2.30% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Jan Stahlberg also recently made the following trade(s):

• On Tuesday, November 25th, Jan Stahlberg purchased 73,099 shares of DiaMedica Therapeutics stock. The stock was bought at an average cost of $8.57 per share, with a total value of $626,458.43.
• On Monday, November 24th, Jan Stahlberg acquired 40,253 shares of DiaMedica Therapeutics stock. The shares were bought at an average cost of $7.89 per share, for a total transaction of $317,596.17.
• On Friday, November 21st, Jan Stahlberg bought 208,872 shares of DiaMedica Therapeutics stock. The stock was purchased at an average price of $7.41 per share, with a total value of $1,547,741.52.
• On Thursday, November 20th, Jan Stahlberg bought 128,426 shares of DiaMedica Therapeutics stock. The stock was purchased at an average cost of $7.41 per share, with a total value of $951,636.66.
• On Wednesday, November 19th, Jan Stahlberg purchased 240,352 shares of DiaMedica Therapeutics stock. The shares were purchased at an average cost of $7.21 per share, for a total transaction of $1,732,937.92.
• On Monday, November 17th, Jan Stahlberg acquired 187,393 shares of DiaMedica Therapeutics stock. The stock was purchased at an average cost of $6.52 per share, with a total value of $1,221,802.36.

DiaMedica Therapeutics Stock Up 3.1%

NASDAQ DMAC opened at $9.35 on Thursday. DiaMedica Therapeutics, Inc. has a 52 week low of $3.19 and a 52 week high of $10.42. The business has a 50 day moving average price of $7.24 and a 200-day moving average price of $5.79. The company has a market cap of $486.95 million, a price-to-earnings ratio of -13.17 and a beta of 1.31.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). On average, equities research analysts anticipate that DiaMedica Therapeutics, Inc. will post -0.59 earnings per share for the current year.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new position in shares of DiaMedica Therapeutics in the 3rd quarter worth approximately $27,000. Police & Firemen s Retirement System of New Jersey bought a new stake in DiaMedica Therapeutics during the second quarter worth $29,000. Bank of America Corp DE boosted its position in DiaMedica Therapeutics by 3,710.3% in the second quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after purchasing an additional 8,274 shares during the last quarter. JPMorgan Chase & Co. bought a new position in DiaMedica Therapeutics in the 2nd quarter valued at $49,000. Finally, Invesco Ltd. bought a new position in DiaMedica Therapeutics in the 2nd quarter valued at $54,000. Institutional investors own 10.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on DMAC shares. Wall Street Zen cut shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. TD Cowen began coverage on DiaMedica Therapeutics in a research note on Thursday, October 30th. They set a “buy” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, October 8th. Cowen began coverage on DiaMedica Therapeutics in a report on Thursday, October 30th. They issued a “buy” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of DiaMedica Therapeutics in a research report on Friday, August 15th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, DiaMedica Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.